323 related articles for article (PubMed ID: 37296869)
1. Metastatic Breast Cancer: Review of Emerging Nanotherapeutics.
Dissanayake R; Towner R; Ahmed M
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296869
[TBL] [Abstract][Full Text] [Related]
2. Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer.
Gupta U; Saren BN; Khaparkhuntikar K; Madan J; Singh PK
J Control Release; 2022 Aug; 348():1089-1115. PubMed ID: 35640765
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer under age 40: a different approach.
Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence.
Abbaspour M; Akbari V
Expert Rev Vaccines; 2022 Mar; 21(3):337-353. PubMed ID: 34932427
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More.
Li Y; Miao W; He D; Wang S; Lou J; Jiang Y; Wang S
Front Bioeng Biotechnol; 2021; 9():680315. PubMed ID: 34150736
[TBL] [Abstract][Full Text] [Related]
7. Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.
Bonni S; Brindley DN; Chamberlain MD; Daneshvar-Baghbadorani N; Freywald A; Hemmings DG; Hombach-Klonisch S; Klonisch T; Raouf A; Shemanko CS; Topolnitska D; Visser K; Vizeacoumar FJ; Wang E; Gibson SB
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473273
[TBL] [Abstract][Full Text] [Related]
8. Therapeutics targeting the metastatic breast cancer bone microenvironment.
Ihle CL; Wright-Hobart SJ; Owens P
Pharmacol Ther; 2022 Nov; 239():108280. PubMed ID: 36116682
[TBL] [Abstract][Full Text] [Related]
9. Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis.
Ščupáková K; Adelaja OT; Balluff B; Ayyappan V; Tressler CM; Jenkinson NM; Claes BS; Bowman AP; Cimino-Mathews AM; White MJ; Argani P; Heeren RM; Glunde K
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34752419
[TBL] [Abstract][Full Text] [Related]
10. Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer.
Ruscitto F; Roda N; Priami C; Migliaccio E; Pelicci PG
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682953
[TBL] [Abstract][Full Text] [Related]
11. Nanotherapeutics for Antimetastatic Treatment.
Yang F; Zhao Z; Sun B; Chen Q; Sun J; He Z; Luo C
Trends Cancer; 2020 Aug; 6(8):645-659. PubMed ID: 32448754
[TBL] [Abstract][Full Text] [Related]
12. Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
Sharma U; Medina-Saenz K; Miller PC; Troness B; Spartz A; Sandoval-Leon A; Parke DN; Seagroves TN; Lippman ME; El-Ashry D
Breast Cancer Res Treat; 2021 Aug; 189(1):63-80. PubMed ID: 34216317
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies.
Huang Y; Li C; Zhang X; Zhang M; Ma Y; Qin D; Tang S; Fei W; Qin J
Int J Pharm; 2023 Apr; 636():122827. PubMed ID: 36925023
[TBL] [Abstract][Full Text] [Related]
14. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.
Wang K; Shi Y; Li ZY; Xiao YL; Li J; Zhang X; Li HY
Eur J Surg Oncol; 2019 Aug; 45(8):1364-1372. PubMed ID: 30837102
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.
Dieci MV; Miglietta F; Griguolo G; Guarneri V
Cancer Treat Rev; 2020 Aug; 88():102064. PubMed ID: 32622272
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.
Johnson RP; Ratnacaram CK; Kumar L; Jose J
Drug Resist Updat; 2022 Sep; 64():100865. PubMed ID: 36099796
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
Krasniqi E; Barchiesi G; Pizzuti L; Mazzotta M; Venuti A; Maugeri-Saccà M; Sanguineti G; Massimiani G; Sergi D; Carpano S; Marchetti P; Tomao S; Gamucci T; De Maria R; Tomao F; Natoli C; Tinari N; Ciliberto G; Barba M; Vici P
J Hematol Oncol; 2019 Oct; 12(1):111. PubMed ID: 31665051
[TBL] [Abstract][Full Text] [Related]
19. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials.
Bukhari SNA
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456698
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment.
Berwart J; Peccatori FA
Ecancermedicalscience; 2019; 13():930. PubMed ID: 31281427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
